Halozyme Therapeutics - HALO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $52.67
  • Forecasted Upside: 32.26 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$39.82
▲ +0.28 (0.71%)

This chart shows the closing price for HALO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Halozyme Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HALO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HALO

Analyst Price Target is $52.67
▲ +32.26% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Halozyme Therapeutics in the last 3 months. The average price target is $52.67, with a high forecast of $60.00 and a low forecast of $42.00. The average price target represents a 32.26% upside from the last price of $39.82.

This chart shows the closing price for HALO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Halozyme Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2022Morgan StanleyInitiated CoverageOverweight$50.00Low
5/26/2022The Goldman Sachs GroupBoost TargetBuy$48.00 ➝ $60.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperform$52.00Low
2/23/2022Piper SandlerLower Target$43.00 ➝ $42.00High
1/26/2022Piper SandlerLower Target$46.00 ➝ $43.00High
12/10/2021JMP SecuritiesReiterated RatingBuy$54.00High
11/24/2021Wells Fargo & CompanyLower TargetOverweight$60.00 ➝ $58.00Low
11/3/2021SVB LeerinkLower TargetOutperform$50.00 ➝ $48.00Low
11/3/2021JMP SecuritiesBoost TargetMarket Outperform$52.00 ➝ $55.00Low
6/14/2021Evercore ISIInitiated CoverageOutperformMedium
5/17/2021Piper SandlerReiterated RatingOverweight ➝ Neutral$50.00 ➝ $48.00N/A
5/17/2021SVB LeerinkInitiated CoverageOutperform$56.00Low
5/11/2021Piper SandlerDowngradeOverweight ➝ Neutral$50.00 ➝ $48.00High
1/25/2021BMO Capital MarketsBoost TargetOutperform$56.00 ➝ $65.00Low
1/21/2021BenchmarkBoost TargetBuy$46.00 ➝ $59.00Low
1/14/2021Piper SandlerBoost TargetOverweight$42.00 ➝ $50.00High
12/17/2020Berenberg BankInitiated CoverageBuy$50.00Medium
12/11/2020Smith Barney CitigroupBoost Target$29.00 ➝ $41.00Medium
11/24/2020BenchmarkBoost TargetBuy$39.00 ➝ $46.00Medium
11/23/2020Piper SandlerBoost Target$37.00 ➝ $42.00Low
11/16/2020Wells Fargo & CompanyBoost TargetOverweight$39.00 ➝ $60.00Low
11/2/2020Piper SandlerBoost TargetOverweight$31.00 ➝ $37.00High
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/11/2020BMO Capital MarketsBoost TargetOutperform$35.00 ➝ $43.00High
8/11/2020Wells Fargo & CompanyBoost TargetOverweight$31.00 ➝ $39.00High
7/2/2020Piper SandlerBoost TargetOverweight$28.00 ➝ $31.00High
7/1/2020BenchmarkInitiated CoverageBuy$39.00Low
6/29/2020Piper SandlerReiterated RatingBuy$28.00High
6/15/2020CitigroupBoost TargetNeutral$18.00 ➝ $26.00Medium
5/12/2020BMO Capital MarketsBoost TargetOutperform$27.00 ➝ $35.00High
5/12/2020JPMorgan Chase & Co.Boost TargetOverweight$22.00 ➝ $23.00High
5/12/2020JMP SecuritiesBoost TargetPositive ➝ Outperform$24.00 ➝ $34.00High
5/4/2020Cantor FitzgeraldBoost TargetOverweight$35.00 ➝ $39.00Low
2/25/2020BarclaysBoost TargetEqual Weight$16.00 ➝ $20.00High
2/25/2020JPMorgan Chase & Co.Lower TargetOverweight$24.00 ➝ $22.00High
2/5/2020Piper SandlerUpgradeNeutral ➝ Overweight$18.00 ➝ $27.00Low
1/27/2020Cantor FitzgeraldReiterated RatingOverweight$27.00 ➝ $35.00Low
1/9/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$17.00 ➝ $24.00High
1/8/2020The Goldman Sachs GroupInitiated CoverageBuy$24.00High
11/5/2019BarclaysUpgradeUnderweight ➝ Equal Weight$17.00 ➝ $16.00High
8/12/2019BarclaysReiterated RatingSell$17.00Medium
7/1/2019Cantor FitzgeraldBoost TargetOverweight$24.00 ➝ $27.00Low
5/8/2019Cantor FitzgeraldReiterated RatingBuyLow
2/28/2019Cantor FitzgeraldSet TargetBuy$24.00Medium
2/27/2019JMP SecuritiesReiterated RatingBuy$21.00Medium
2/4/2019Cantor FitzgeraldReiterated RatingBuy$24.00High
12/5/2018Cantor FitzgeraldReiterated RatingBuy$27.00Low
11/26/2018Cantor FitzgeraldSet TargetBuy$27.00High
11/6/2018Cantor FitzgeraldSet TargetBuy$27.00High
10/31/2018Cantor FitzgeraldSet TargetBuy$27.00Low
10/25/2018Cantor FitzgeraldSet TargetBuy$27.00Low
10/19/2018Piper Jaffray CompaniesReiterated RatingNeutral ➝ NeutralLow
10/18/2018Piper Jaffray CompaniesInitiated CoverageHold$17.00High
10/2/2018Cantor FitzgeraldSet TargetBuy$27.00Medium
8/22/2018Cantor FitzgeraldInitiated CoverageOverweight$27.00High
8/8/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$19.00 ➝ $21.00Medium
5/11/2018BarclaysDowngradeEqual Weight ➝ Underweight$19.00High
2/22/2018BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$18.00 ➝ $19.00Low
2/21/2018JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$19.00 ➝ $22.00Low
1/24/2018Deutsche Bank AktiengesellschaftSet TargetBuy$21.00Low
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$20.00High
11/22/2017BarclaysDowngradeOverweight ➝ Hold$16.00 ➝ $19.00N/A
11/8/2017BMO Capital MarketsBoost TargetMarket Perform$15.00 ➝ $18.00N/A
10/16/2017Piper Jaffray CompaniesBoost TargetOverweight ➝ Overweight$26.00 ➝ $29.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/7/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/4/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Halozyme Therapeutics logo
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Read More

Today's Range

Now: $39.82
Low: $39.28
High: $40.25

50 Day Range

MA: $42.71
Low: $38.53
High: $51.70

52 Week Range

Now: $39.82
Low: $31.36
High: $52.98

Volume

24,453 shs

Average Volume

1,132,839 shs

Market Capitalization

$5.49 billion

P/E Ratio

15.74

Dividend Yield

N/A

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Halozyme Therapeutics?

The following equities research analysts have issued stock ratings on Halozyme Therapeutics in the last twelve months: JMP Securities, Morgan Stanley, Piper Sandler, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for HALO.

What is the current price target for Halozyme Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Halozyme Therapeutics in the last year. Their average twelve-month price target is $52.67, suggesting a possible upside of 32.3%. The Goldman Sachs Group, Inc. has the highest price target set, predicting HALO will reach $60.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $42.00 for Halozyme Therapeutics in the next year.
View the latest price targets for HALO.

What is the current consensus analyst rating for Halozyme Therapeutics?

Halozyme Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HALO will outperform the market and that investors should add to their positions of Halozyme Therapeutics.
View the latest ratings for HALO.

What other companies compete with Halozyme Therapeutics?

How do I contact Halozyme Therapeutics' investor relations team?

Halozyme Therapeutics' physical mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company's listed phone number is 858-794-8889 and its investor relations email address is [email protected] The official website for Halozyme Therapeutics is www.halozyme.com. Learn More about contacing Halozyme Therapeutics investor relations.